The group has extensive experience in the study and management of viral and bacterial infections, and its scientific activity is translated into applicability to pediatric health, through the:
GENVIP has setup a Clinical Trials Unit that is primarily focused on vaccines. This unit channels most of the clinical trials conducted in Spain on pediatric vaccines, from Phase 1 to Phase 3. In addition, GENVIP partners with developers in the design of protocols and clinical development programs for a number of vaccine candidates.
To date we have conducted work on pathogens such as meningococci (MENDICOS, EUCLIDS, ESIGEM, PERFORM projects), pneumococci (PNEUMOREG, CAPPRIC, ESIGEM project), pertussis (BOOSTRITOS project), respiratory syncytial virus (GENDRES, POCID, RESVINEXT, RESVIOMICS, RESCEU, PROMISE), influenza virus (FLUGAL project, GENDRES), enterovirus (ENTEROGEN project), rotavirus (ROTACOST, ROTAGEN projects) or SARS-COV-2 (GEN-COVID project), among others.
More info
The group’s main purpose is to increase the knowledge of the pathogenesis of diseases affecting children from different perspectives, using an '-omics' approach. This approach involves multiple '-omics' tools (transcriptomics, genomics, epigenomics, etc.), and can help to understand the molecular mechanisms underlying the host response to infection and explore, from different perspectives, if there are genomic, transcriptomic and/or epigenetic biomarkers that may be related to the diagnosis, prognosis and evolution of infection.
The GENVIP team has extensive experience in the translational approach to infectious diseases and its applicability for the benefit of the patient. In this regard, GENVIP has contributed with several translational projects to the development of diagnostic tests based on the host response to infection.
The study of infectious diseases at GENVIP not only involves stable research lines but also includes numerous partnerships with international reference centers such as the Imperial College London, Ospedale Pediatrico Bambino Gesú, PENTA Fondazione, the Genomic Institute of Singapore, Rabdoud University, Oxford Gene Technology, ReSVinet, Genomic Systems or the National Children's Hospital of Ohio, among others, as well as with the main Spanish pediatric reference hospitals.
GENVIP partners with the World Health Organization (WHO) in Europe in scheduled interventions and acute crisis related to vaccines and infectious diseases as a WHO Collaborating Centre for Vaccine Safety.
GENVIP manages and coordinates a number of national and international multicenter clinical networks to collect samples from patients with different diseases in childhood.
More info
Applying this "omics" approach to the study of vaccines helps us to better understand the patient's response to different vaccine antigens, discover new markers of protection and establish individualized strategies for protection by vaccination. The study of their heterologous properties is another of GENVIP’S research lines in the field of vaccines, particularly on BCG, rotavirus and pneumococcus vaccines, but also on the development of the appropriate models to apply the paradigm to new vaccines.
GENVIP partners with the World Health Organization (WHO) in Europe in scheduled interventions and acute crisis related to vaccines and infectious diseases as a WHO Collaborating Centre for Vaccine Safety.
More info
The GENVIP group is made of experts in biology/genetics, bioinformatics and mathematics/statistics with extensive experience in data management. They have expertise in the analysis of genomics, transcriptomics and epigenomics data from high-throughput and NGS platforms. The group has developed software applications, internal lines for the analysis of genomics / transcriptomics data and predictive bioinformatics models applied to different diseases.
More info
GENVIP develops several projects in the field of population genetics and other biomedical applications. The aim is to understand human genetic variability and its potential impact on biomedical projects. The group also works in several lines related to the study of human variability in populations of different continents, simulation studies for the analysis of ancestry and its biomedical applications, population stratification and its effects in case-control studies, statistical power, and epistasis.
More info
One of GENVIP's research lines is focused on the study of progressive osseous heteroplasia (POH) and heterotopic ossification. POH is an ultra-rare disease in which extra-skeletal bone is formed from mesodermal tissue. There is no effective or preventive treatment for this disease. We are using a translational "-omics" approach to try to characterize the disease and identify therapeutic targets to improve the quality of life of patients.
More info
GENVIP has several open research lines in this field, with active studies in diseases such as asthma or Food Protein-Induced Enterocolitis Syndrome (FPIES), which is a common food allergy poorly understood from a pathophysiological point of view. It is a life-threatening disease for which there is no diagnostic test and its clinical evolution cannot be predicted.
More info
Sensogenomics seeks, for the first time, to delve into the genetic bases that exist behind the musical stimulus and to understand the biological mechanisms that underlie this stimulus and our biological relationship with music.
Currently, the first step of the research focuses on music and the expression of genes in the general population and different contexts of human pathology such as cancer, Alzheimer's, autism spectrum disorder (ASD), brain damage, etc. Subsequently, we will study characteristics (phenotypes) related to music, for which there are already candidate susceptibility genes (perfect pitch, etc). It has been reported that some of these phenotypes are related to specific pathologies, such as ASD, Williams Syndrome, etc.